Related Experiment Videos
A p34(cdc2) survival checkpoint in cancer
Daniel S O'Connor1, Nathan R Wall, Andrew C G Porter
1Boyer Center for Molecular Medicine, Yale University School of Medicine, 295 Congress Avenue, New Haven, Connecticut 06536, USA.
Cancer Cell
|August 2, 2002
Summary
Microtubule stabilization activates a survival pathway involving p34(cdc2) kinase and survivin. Inhibiting p34(cdc2) kinase triggers cancer cell apoptosis, improving treatments.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- The spindle checkpoint monitors microtubule assembly during mitosis.
- This checkpoint's role in cancer cell survival is not fully understood.
- Microtubule-stabilizing agents are used in cancer therapy.
Purpose of the Study:
- To elucidate the mechanism by which microtubule stabilization influences cancer cell survival.
- To identify key molecular players in the survival pathway triggered by microtubule stabilization.
- To evaluate the therapeutic potential of targeting this survival pathway.
Main Methods:
- Investigated the role of p34(cdc2) kinase and survivin in response to microtubule stabilization.
- Utilized pharmacologic, genetic, and molecular ablation techniques to inhibit p34(cdc2) kinase.
- Assessed apoptosis induction, tumor growth suppression, and in vivo toxicity in mouse models.
Main Results:
- Microtubule stabilization activates a survival pathway dependent on p34(cdc2) kinase and survivin expression.
- Ablation of p34(cdc2) kinase activity leads to massive apoptosis, independent of p53.
- Inhibition of p34(cdc2) kinase suppressed tumor growth and demonstrated no toxicity in mice.
Conclusions:
- Microtubule stabilization activates a p34(cdc2) kinase-dependent survival pathway in cancer cells.
- Targeting this survival checkpoint with p34(cdc2) kinase inhibitors offers a safe and effective strategy.
- Combining p34(cdc2) kinase inhibitors with microtubule-stabilizing agents can enhance cancer therapy efficacy.